

## Asarina Pharma - Two More to Go

Redeye deep-dives into the Tourette indication and includes it in our Sum of the Parts (SOTP) valuation. The inclusion of Tourette drives the increase in our Base Case. In this update, we also preview the upcoming results in Menstrual Migraine. Notably, both phase 2 studies in Tourette and Menstrual Migraine are funded.

**Read more and download the Research Update.**

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

**Asarina Pharma - Two More to Go**